Hormone replacement therapy tied to Alzheimer's risk, study says, but experts urge caution

An observational study on hormone replacement therapy in nearly 85,000 postmenopausal Finnish women found that those on such therapy had a very small increased risk for Alzheimer's, especially when using combination hormones long-term.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news

Related Links:

The study found that women taking hormone replacement therapy had a 9 percent to 17 percent higher risk of developing Alzheimer's disease. In women who began taking hormone therapy before age 60, this increased risk was tied to use of HRT for a decade or longer.
Source: WebMD Health - Category: Consumer Health News Source Type: news
An estimated one million women in Britain and five per cent of women over the age of 50 in the US take hormone replacement therapy to help relieve menopause symptoms.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
In conclusion, HSC ageing is characterised by reduced self-renewal, myeloid and platelet HSC skewing, and expanded clonal haematopoiesis that is considered a preleukaemic state. The underlying molecular mechanisms seem to be related to increased oxidative stress due to ROS accumulation and DNA damage, which are influenced by both cell- and cell non-autonomous mechanisms such as prolonged exposure to infections, inflammageing, immunosenescence, and age-related changes in the HSC niche. Thus, HSC ageing seems to be multifactorial and we are only beginning to connect all the dots. The Price of Progress or the Waste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In the U.S., two-thirds of people with Alzheimer’s disease are women, according to the Alzheimer’s Association. For decades, experts have explained the gender divide by the fact that women also tend to live longer than men, and the biggest risk factor for Alzheimer’s is age. “Everyone brushed it off to the fact that women were living longer,” says Rachel Whitmer, professor of epidemiology at University of California Davis. “Now science is saying, wait, that’s not the end of the story.” Pregnancy, according to two of the latest studies on the issue, may have something to do wi...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Brain healthytime Source Type: news
CONCLUSIONS: Proteomic biomarkers in participants with cognitive impairment suggest roles for insulin, and vascular signaling pathways, some of which are similar to findings in Alzheimer's disease. A better understanding of the pathogenic mechanisms of CI in OSAS will help focus clinical trials needed in this patient population. PMID: 29968150 [PubMed - as supplied by publisher]
Source: Genomics Proteomics ... - Category: Genetics & Stem Cells Authors: Tags: Sleep Breath Source Type: research
ConclusionsProteomic biomarkers in participants with cognitive impairment suggest roles for insulin, and vascular signaling pathways, some of which are similar to findings in Alzheimer ’s disease. A better understanding of the pathogenic mechanisms of CI in OSAS will help focus clinical trials needed in this patient population.
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
Authors: Lozupone M, La Montagna M, D'Urso F, Piccininni C, Sardone R, Dibello V, Giannelli G, Solfrizzi V, Greco A, Daniele A, Quaranta N, Seripa D, Bellomo A, Logroscino G, Panza F Abstract INTRODUCTION: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondement...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
A seven-year US study has found women who take HRT experience fewer age-related changes to the brain and fewer of them had an accumulation of toxic proteins linked to Alzheimer's Disease.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Abstract Several lines of investigation have shown a protective role for estrogen in Alzheimer's disease through a number of biological actions. This review examines studies of the role of estrogen-related factors in age at onset and risk for Alzheimer's disease in women with Down syndrome, a population at high risk for early onset of dementia. The studies are consistent in showing that early age at menopause and that low levels of endogenous bioavailable estradiol in postmenopausal women with Down syndrome are associated with earlier age at onset and overall risk for dementia. Polymorphisms in genes associated wi...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Tags: Free Radic Biol Med Source Type: research
Throughout decades of study, hormone therapy (HT), often but not always the same as hormone replacement therapy (HRT), has been glorified and demonized in turn. The information that doctors receive has come from ongoing studies that seemed to offer over time radically conflicting results. A new study may add more confusion since this study has found that not only does HT given near menopause create changes in a woman’s brain, but motherhood itself creates changes. Read full article on how changing hormones can alter the risk of Alzheimer's: Support a caregiver or jump start discussion in support groups with real stor...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
More News: Alzheimer's | Finland Health | Health | Hormone Replacement Therapy | Hormones | Study | Women